When It Comes To A COVID-19 Vaccine For Kids, It Will Be Awhile
US FDA will be cautious about development of a COVID-19 vaccine for children, Commissioner Hahn says at the Financial Times US Pharma And Biotech Summit.
You may also be interested in...
An ex-member of the strategic advisory group to WHO's Global Vaccine Safety Initiative and infectious diseases expert shares his views on COVID-19 vaccines, shaping pediatric trials and areas that may need attention.
Sponsors are moving to younger populations as the adult clinical trials near enrollment goals; Moderna’s CEO says data in children younger than 12 will be slow to emerge.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.